Tag: 822.9402

An ultra-sensitive rifampicin electrochemical sensor based on Fe₃O₄ nanoparticles anchored Multiwalled Carbon nanotube modified glassy carbon electrode was written by Alizadeh, Marzie;Asrami, Padideh Naderi;Altuner, Elif Esra;Gulbagca, Fulya;Tiri, Rima Nour Elhouda;Aygun, Aysenur;Kaynak, Idris;Sen, Fatih;Cheraghi, Somaye. And the article was included in Chemosphere in 2022.Category: piperazines This article mentions the following:

This study aimed to guide future sensor studies against other pharmaceutical drugs by synthesizing Fe3O4NPs@MWCNT metallic nanoparticles (NPs). Side damage caused by excessive accumulation of tuberculosis drugs in the body can cause clots in the organs, and cause serious damage such as heart attack and respiratory failure, and threaten human life. Therefore, the development of sensors sensitive to various antibiotics in this study is important for human health. In this study, the sensitivity of Fe3O4 NPs to tuberculosis drug (rifampicin) was evaluated by catalytic reaction using bare/GCE, MWCNT/GCE, and Fe3O4NPs@MWCNT/GCE electrodes. First of all, Fe3O4 NPs were successfully synthesized for the study and MWCNT/GCE and Fe3O4 NPs@MWCNT/GCE electrodes were formed with the modification of the MWCNT support material. It was observed that the Fe3O4 NPs@MWCNT/GCE electrode gave the highest signal against the other electrodes. The morphol. structure of Fe3O4 NPs was determined by various characterization techniques such as Transmission Electron Microscopy (TEM), Fourier Transmission IR Spectroscopy (FTIR), UV-visible (UV-Vis), and X-ray differential (XRD) and the obtained NPs were used for sensor studies, and it was observed that the current intensity increased as the scanning speed of each electrode increased in CV and DPV measurements. The average size of Fe3O4 NPs was found to be 7.32 ± 3.2 nm. Anodic current peaks occurred in the linear range of 2-25 μM. According to the results obtained from the measurements, the limit of detection (LOD) value was calculated as 0.64 μM limit of quantification (LOQ) 1.92 μM. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Category: piperazines).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial was written by Ntinginya, Nyanda Elias;te Brake, Lindsey;Sabi, Issa;Chamba, Nyasatu;Kilonzo, Kajiru;Laizer, Sweetness;Andia-Biraro, Irene;Kibirige, Davis;Kyazze, Andrew Peter;Ninsiima, Sandra;Critchley, Julia A.;Romeo, Renee;van de Maat, Josephine;Olomi, Willyhelmina;Mrema, Lucy;Magombola, David;Mwayula, Issakwisa Habakkuk;Sharples, Katrina;Hill, Philip C.;van Crevel, Reinout;On behalf of the PROTID Consortium. And the article was included in Trials in 2022.Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins This article mentions the following:

Diabetes mellitus (DM) increases the risk of tuberculosis (TB) and will hamper global TB control due to the dramatic rise in type 2 DM in TB-endemic settings. In this trial, we will examine the efficacy and safety of TB preventive therapy against the development of TB disease in people with DM who have latent TB infection (LTBI), with a 12-wk course of rifapentine and isoniazid (3HP). The ‘Prevention of tuberculosis in diabetes mellitus (PROTID) consortium will randomise 3000 HIV-neg. eligible adults with DM and LTBI, as evidenced by a pos. tuberculin skin test or interferon gamma release assay, to 12 wk of 3HP or placebo. Participants will be recruited through screening adult patients attending DM clinics at referral hospitals in Tanzania and Uganda. Patients with previous TB disease or treatment with a rifamycin medication or isoniazid (INH) in the previous 2 years will be excluded. The primary outcome is the occurrence of definite or probable TB disease; secondary outcome measures include adverse events, all-cause mortality and treatment completion. The primary efficacy anal. will be intention-to-treat; per-protocol analyses will also be carried out. We will estimate the ratio of TB incidence rates in intervention and control groups, adjusting for the study site using Poisson regression. Results will be reported as efficacy estimates (1-rate ratio). Cumulative incidence rates allowing for death as a competing risk will also be reported. Approx. 1000 LTBI-neg., HIV-neg. participants will be enrolled consecutively into a parallel cohort study to compare the incidence of TB in people with DM who are LTBI neg. vs pos. A number of sub-studies will be conducted among others to examine the prevalence of LTBI and active TB, estimate the population impact and cost-effectiveness of LTBI treatment in people living with DM in these African countries and address gaps in the prevention and therapeutic management of combined TB-DM. PROTID is anticipated to generate key evidence to guide decisions over the use of TB preventive treatment among people with DM as an important target group for better global TB control. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Piperazines are very broad chemical group, covering a wide range of drugs from antidepressants to antihistamines. The connecting property of all these chemicals is the presence of a piperazine functional group.Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study. was written by Tu, Pham Hien Trang;Anlay, Degefaye Zelalem;Dippenaar, Anzaan;Conceição, Emilyn Costa;Loos, Jasna;Van Rie, Annelies. And the article was included in BMC infectious diseases in 2022.Application of 13292-46-1 This article mentions the following:

BACKGROUND: Bedaquiline (BDQ) is a core drug for rifampicin-resistant tuberculosis (RR-TB) treatment. Accurate prediction of a BDQ-resistant phenotype from genomic data is not yet possible. A Bayesian method to predict BDQ resistance probability from next-generation sequencing data has been proposed as an alternative. METHODS: We performed a qualitative study to investigate the decision-making of physicians when facing different levels of BDQ resistance probability. Fourteen semi-structured interviews were conducted with physicians experienced in treating RR-TB, sampled purposefully from eight countries with varying income levels and burden of RR-TB. Five simulated patient scenarios were used as a trigger for discussion. Factors influencing the decision of physicians to prescribe BDQ at macro-, meso- and micro levels were explored using thematic analysis. RESULTS: The perception and interpretation of BDQ resistance probability values varied widely between physicians. The limited availability of other RR-TB drugs and the high cost of BDQ hindered physicians from altering the BDQ-containing regimen and incorporating BDQ resistance probability in their decision-making. The little experience with BDQ susceptibility testing and whole-genome sequencing results, and the discordance between phenotypic susceptibility and resistance probability were other barriers for physicians to interpret the resistance probability estimates. Especially for BDQ resistance probabilities between 25% and 70%, physicians interpreted the resistance probability value dynamically, and other factors such as clinical and bacteriological treatment response, history of exposure to BDQ, and resistance profile were often considered more important than the BDQ probability value for the decision to continue or stop BDQ. In this grey zone, some physicians opted to continue BDQ but added other drugs to strengthen the regimen. CONCLUSIONS: This study highlights the complexity of physicians’ decision-making regarding the use of BDQ in RR-TB regimens for different levels of BDQ resistance probability.. Ensuring sufficient access to BDQ and companion drugs, improving knowledge of the genotype-phenotype association for BDQ resistance, availability of a rapid molecular test, building next-generation sequencing capacity, and developing a clinical decision support system incorporating BDQ resistance probability will all be essential to facilitate the implementation of BDQ resistance probability in personalizing treatment for patients with RR-TB. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Application of 13292-46-1).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 °C and boils at 125–130 °C. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Application of 13292-46-1

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mechanisms of linezolid resistance in Staphylococcus capitis with the novel mutation C2128T in the 23S rRNA gene in China was written by Han, Xiao;Zou, Guiling;Liu, Jiaren;Yang, Chun;Du, Xuefei;Chen, Guoyu;Sun, Zhe;Zhang, Xinyu;Sun, Yu;Zhang, Wanying;Jiang, Xiaofeng. And the article was included in BMC Microbiology in 2022.Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins This article mentions the following:

The objective of this study was to investigate the mol. characteristics and potential resistance mechanisms of linezolid-resistant (LZR) Staphylococcus capitis isolates from a tertiary hospital in China. S. capitis isolates were obtained from clin. patient specimens; three of the isolates came from blood cultures and one from the hydrothorax. The agar dilution and E-test methods were used to identify antibiotic resistance. The chloramphenicol-florfenicol resistance (cfr) gene carrier status of the strains was determined by PCR. Whole-genome sequencing (WGS) was used to identify point mutations and L3, L4, and L22 mutations and to study the genetic environment of the cfr gene and the relationships between strains. The 4 isolates obtained in this study were all linezolid-resistant Staphylococcus strains. A similar of susceptibility profile pattern was observed in all four S. capitis strains, each of which exhibited a multidrug-resistant phenotype. A potentially novel mutation, C2128T, was identified, and the cfr genes of S. capitis strains were all pos. Addnl., the same mutations (C2128T and G2600T) were identified in all 23S rRNA sequences of the isolates, whereas mutations were lacking in the L3, L4, and L22 ribosomal proteins. The genetic environments surrounding cfr were identical in all four isolates. A schematic diagram of the phylogenetic tree showed that they were closely related to AYP1020, CR01, and TW2795, and a total of seven drug resistance genes were identified in these strains. The study indicated that the resistance of the Staphylococcus capitis strains to linezolid was caused by multiple mechanisms, and a potential novel mutation, C2128T, that may have an impact on bacterial resistance was identified. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 °C and boils at 125–130 °C. Piperazines are very broad chemical group, covering a wide range of drugs from antidepressants to antihistamines. The connecting property of all these chemicals is the presence of a piperazine functional group.Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis was written by Goodall, Ruth L.;Sanders, Karen;Bronson, Gay;Gurumurthy, Meera;Torrea, Gabriela;Meredith, Sarah;Nunn, Andrew;Rusen, I. D.;on behalf of the STREAM Trial Team. And the article was included in Trials in 2022.Safety of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins This article mentions the following:

Results from the STREAM stage 1 trial showed that a 9-mo regimen for patients with rifampicin-resistant tuberculosis was non-inferior to the 20-mo regimen recommended by the 2011 WHO treatment guidelines. Similar levels of severe adverse events were reported on both regimens suggesting the need for further research to optimize treatment. Stage 2 of STREAM evaluates two addnl. short-course regimens, both of which include bedaquiline. Throughout stage 2 of STREAM, new drug choices and a rapidly changing treatment landscape have necessitated changes to the trial’s design to ensure it remains ethical and relevant. This paper describes changes to the trial design to ensure that stage 2 continues to answer important questions. These changes include the early closure to recruitment of two trial arms and an adjustment to the definition of the primary endpoint. If the STREAM exptl. regimens are shown to be non-inferior or superior to the stage 1 study regimen, this would represent an important contribution to evidence about potentially more tolerable and more efficacious MDR-TB regimens, and a welcome advance for patients with rifampicin-resistant tuberculosis and tuberculosis control programs globally. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Safety of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Although many piperazine derivatives occur naturally, piperazine itself can be synthesized by reacting alcoholic ammonia with 1,2-dichloroethane, by the action of sodium and ethylene glycol on ethylene diamine hydrochloride, or by reduction of pyrazine with sodium in ethanol.Safety of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Enhanced photodegradation of rifampicin and co-trimoxazole by ZnO/ZnMn₂O₄/ZnS-PVA and its genotoxicity studies on Allium cepa was written by Harini, G.;Syed, Asad;Rahiman, M. Kalil;Bahkali, Ali H.;Elgorban, Abdallah M.;Varma, Rajender S.;Khan, S. Sudheer. And the article was included in Chemosphere in 2022.Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins This article mentions the following:

Oxygen vacancies and its associated defect states have a great influence on the electronic and structural aspects of semiconductor photocatalysts, yet there is paucity of investigations about the influence of the defect states on their photocatalytic properties. Herein, this study reports the hierarchical fabrication of oxygen vacancy enriched ZnO/ZnMn₂O₄/ZnS-PVA nanocomposite (NCs) for the enhanced photodegradation of rifampicin and co-trimoxazole. The formation of lattice expansion induced oxygen vacancies and its associated Urbach tail energy, and n-p-n heterojunction-based S-scheme charge transfer path synergistically contributed to the boosted photocatalytic performance of the as prepared NCs. The photocatalytic performance of the nanomaterial towards rifampicin and co-trimoxazole has been determined to be 80% and 90% under visible light irradiation, resp. Furthermore, various operating parameters including the concentration of NCs and drug, pH and interference of various ions have been evaluated. The degraded product intermediates have been elucidated by GC-MS anal. The toxicity of the as-prepared nanomaterials has been evaluated by treating the samples with root tips of Allium cepa, where the NCs was found to be non-toxic. The study provides a new-fangled insight on the preparation and fabrication of non-toxic and defect rich nanomaterials which may help stimulate this area of research. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Quality Control of 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

GC-MS analysis and antimicrobial activities of a Rosmarinus officinalis L. essential oil from Kashan Region (Iran) was written by Ghavam, Mansureh. And the article was included in Biochemical Systematics and Ecology in 2022.SDS of cas: 13292-46-1 This article mentions the following:

The essential oil (EO) from Rosmarinus officinalis L. gains attention as preservative in food and pharmaceutical industry. As specialized metabolites biosynthesis is mostly affected by abiotic factors (e.g. climate, temperature, light, etc.), our efforts have been devoted to study was the chem. composition and the antimicrobial activity of the EO from R. officinalis in Kashan, Iran. Twenty-nine components were identified by gas chromatog.-mass spectrometry (GC-MS) anal. The main compounds included α-pinene (19.41%), 1,8-cineole (15.40%), camphor (8.87%), borneol (8.48%) and verbenone (8.8%). The studied EO was active against Gram-pos. bacteria Bacillus subtilis, Staphylococcus aureus and Staphylococcus epidermidis. Based on MIC values, the inhibitory effect against Pseudomonas aeruginosa was higher than that of rifampin. The antimicrobial activity of rosemary EO from Kashan Region (Iran) encourages its cultivation among local farmers to promote a local production In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1SDS of cas: 13292-46-1).

8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. SDS of cas: 13292-46-1

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics